A low osmolar, nonionic, iodinated contrast agent, the OMNIPAQUE has been used in more than 250 million patients worldwide. Its indications include a broad range of intravascular diagnostic procedures such as coronary angiography, spinal cord imaging and body cavity procedures including shoulder and knee joints. The injection is approved for use in adults and children.
On Jan. 10, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Contrast Management in Modern PCI." ...
January 11, 2024 
On Jan. 10, 2024, Diagnostic and Interventional Cardiology presented a webinar on "Contrast Management in Modern PCI." ...
December 08, 2023 
May 3, 2016 — The global market for contrast media injectors is set to increase from $830 million in 2015 to almost $1.8 ...
May 03, 2016 
October 1, 2015 — Galt Medical has partnered with Health Line International Corp. and launched the Nexus CT Midline ...
October 01, 2015 
There have been several recent advances with contrast media injector technology, including cutting costs by reducing ...
February 10, 2015 
Automated contrast media injectors are used in cardiac imaging to help improve patient safety and enhance image quality ...
July 08, 2010